AbD Serotec Expands Range of HuCAL Antibodies Used in Clinical Diagnostic Kits

Thursday, 15. March 2012 07:30
MorphoSys AG /
AbD Serotec Expands Range of HuCAL Antibodies Used in Clinical Diagnostic Kits
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that a
HuCAL antibody generated by its division for research and diagnostic antibodies,
AbD Serotec, has been included in a clinical diagnostic test in the area of
maternal health screening by a major diagnostic supplier. The product is CE
marked and available within the EU and non-regulated countries. AbD Serotec
receives royalties on product sales and will continuously supply the customer
with recombinant antibody material.

"Today's news further increases the number of clinical diagnostic kits relying
on a HuCAL antibody as an essential component," commented Dieter Feger, Head of
AbD Serotec. "The market entry of yet another test system including a HuCAL
antibody is a further significant step forward for our recombinant technology in
the field of in vitro diagnostics. AbD Serotec is committed to continue driving
this process as we believe the HuCAL technology enables the generation of
superior diagnostics reagents."



About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company'sAbD Serotec unit uses HuCAL and other antibody technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipeline of more than 70 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just
a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of tomorrow.
MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For
regular updates about MorphoSys, visit http://www.morphosys.com


HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®) and
arYla(®) are registered trademarks of MorphoSys. Ylanthia(®) and 100 billion
high potentials(TM) are trademarks of MorphoSys AG.


Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.


This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.



For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com


--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Media Release:
http://hugin.info/130295/R/1593988/501690.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1593988]
Related Links: MorphoSys AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.